FDA advisory panel convenes to discuss whether Biogen Alzheimer's drug should be approved ...Middle East

Yahoo - News
FDA advisory panel convenes to discuss whether Biogen Alzheimers drug should be approved
The agency is expected to make its decision by March, with aducanumab poised to become the first new treatment for the disease in decades and the first that appears to be able to slow progression of the fatal, mind-wasting condition, should it win U.S. approval. Biogen shares were halted ahead of the advisory panel meeting. Alzheimer's disease is the sixth leading cause of death in the United States and there is "a profound and enormous unmet medical need" for new treatments, Billy Dunn, director of neurology products for the FDA's Center for Drug Evaluation and Research, said during the meeting.

Hence then, the article about fda advisory panel convenes to discuss whether biogen alzheimer 39 s drug should be approved was published today ( ) and is available on Yahoo ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA advisory panel convenes to discuss whether Biogen Alzheimer's drug should be approved )

Apple Storegoogle play

Last updated :

Also on site :